Viking Therapeutics, Inc. (VKTX) Q2 2018 Earnings Results

Viking Therapeutics Misses on EPS, Stock Down 4.72%

Viking Therapeutics reported a loss per share of $0.13, but did not disclose revenue figures. The stock fell 4.72% following the earnings report, likely due to the absence of guidance and detailed financial metrics, which may have raised concerns among investors about the company's direction and performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.13	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management emphasized the importance of their clinical programs but did not offer specific financial guidance. The lack of detailed information may have contributed to investor uncertainty.

Management did not provide specific revenue figures or guidance for the upcoming quarters.

The focus remains on ongoing clinical trials and product development.

Viking Therapeutics Misses on EPS, Stock Down 4.72%

Key numbers

Management commentary

Viking Therapeutics, Inc.

More earnings this week

Viking Therapeutics Misses on EPS, Stock Down 4.72%

Key numbers

Management commentary